Sep 17,2019

Medtronic Introduces Envision™ Pro Continuous Glucose Monitoring (CGM) System in Europe

Medtronic plc, the global leader in medical technology, services and solutions, today announced the Envision™ Pro Continuous Glucose Monitoring (CGM) system — a fully disposable, zero calibration professional CGM system — has obtained CE (Conformité Européenne) Mark approval. Medtronic will begin commercial release in Europe and the Middle East this fall, subject to local regulatory requirements1. This new technology will empower healthcare professionals and their patients with either type 1 and type 2 diabetes to see accurate glucose levels and trends over time to develop more optimal diabetes therapy plans.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 17,2019

One Drop Launches Global Commercial Partnership with Bayer and Announces $40M in Series B Financing

One Drop, a leader in the development of digital therapeutic solutions for diabetes and other chronic conditions, today announced $40 million in Series B financing, led by Bayer, one of the largest pharmaceutical companies in the world. Bayer has also entered a commercial licensing agreement to use One Drop’s platform in Bayer’s global bio-digital efforts in therapeutic areas such as oncology, cardiovascular disease, and women’s health. Stefan Oelrich, the President of Bayer Pharmaceuticals, will join One Drop’s Board of Directors.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Sep 18,2019

DarioHealth Awarded U.S. Patent for Optical Transmission of Data Between a Sensor and Smart Device

DarioHealth Corp. ("DarioHealth" or "Dario") (Nasdaq: DRIO), a leading, global digital therapeutics company, today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office titled "Systems and Methods for Enabling Optical Transmission of Data Between a Sensor and a Smart Device." The patent will allow Dario to develop paired smartphone devices that can collect and analyze real-time medical data and provide immediate and highly detailed, personalized data reports to the user. Once collected, this data can be shared with healthcare providers through the DarioEngage™ platform to facilitate digital health interventions based on the data analysis.

PRODUCT

#dtx

View Analyst & Ambassador Comments
Go to original news
Sep 18,2019

MiniMed™ 670G System European Real-World Data Shows 73% Time in Range, Beyond Recommended Targets

Medtronic plc, the global leader in medical technology, services and solutions today announced real-world clinical outcomes on European patients for the MiniMed™ 670G system. The European data showed an average Time in Range of 73%, a result that exceeds the recommended Time in Range consensus guidelines of 70% that were recently published. The real-world data of 4,369 patients showed an average estimated HbA1c of 6.9%*, also surpasses the recommended target.

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Sep 18,2019

Tandem Diabetes Care Announces Publication of Real-world Basal-IQ Predictive Low Glucose Suspend Technology Data in Diabetes Technology and Therapeutics Journal

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, today announced publication of real-world data from more than 8,000 users of the t:slim X2™ insulin pump with Basal-IQ® predictive low-glucose suspend technology in the medical journal Diabetes Technology and Therapeutics. The results demonstrate sustained reductions in hypoglycemia across all groups using Basal-IQ technology, regardless of prior therapy. A specific sub-analysis of t:slim X2 pump users who remotely updated their pump software to Basal-IQ technology revealed a 45 percent relative risk reduction in hypoglycemia and a 71 percent relative risk reduction of hypoglycemic events. The reductions in hypoglycemic outcomes with real-world use exceeded reductions observed in the controlled pivotal study for Basal-IQ technology.

CLINICAL STUDY

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Sep 23,2019

DarioHealth CEO Erez Raphael Presents to Digital Therapeutics Leaders at DTx East 2019

DarioHealth Corp., a leading, global digital therapeutics company, today announced that Erez Raphael, DarioHealth's Chief Executive Officer, will be a speaker at the second annual DTx East 2019 conference taking place at Harvard Medical School in Boston, MA from September 24-26, 2019.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Sep 30,2019

Insulet to Announce Third Quarter 2019 Financial Results on November 5, 2019

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the third quarter of 2019 on November 5, 2019 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

View Analyst & Ambassador Comments
Go to original news
Sep 30,2019

Data from Ascensia Diabetes Care Shows Potential Benefits from Using the CONTOUR®PLUS ONE BGMS With the Health2Sync App

At the 21st Diabetes and Cardiovascular Risk Factors – East Meets West Symposium, Ascensia Diabetes Care has presented data from two studies, one analyzing the accuracy of blood glucose monitoring systems (BGMSs) in the low blood glucose range (LBGR) using the probability method, and the other analyzing the use of the CONTOUR®PLUS ONE BGMS with the Health2Sync (H2S) mobile app in people with type 1 diabetes in Hong Kong.

CLINICAL STUDY

#bgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 30,2019

Voluntis reports business review and financial results for the first half of 2019

The first half of 2019, Voluntis generated revenue of €2.0 million compared with €2.2 million for the same period in 2018. The Group is still in a transition phase towards a turnover that consists more of recurring revenues related to the marketing of its products than of pre-launch revenues related to product development and approval.

View Analyst & Ambassador Comments
Go to original news
Sep 30,2019

Senseonics Announces the Completion of US Patient Enrollment in the PROMISE 180-Day Sensor Clinical Study

Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the completion of patient enrollment in the Eversense PROMISE 180-day sensor Clinical Study.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES